Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)

BACKGROUND: Focus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique, additive burden. A composite measure of total pain burden (TPB; frequency, severity, and duration) may provide a more comprehensive characterization of pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ailani, Jessica, Andrews, J. Scott, Rettiganti, Mallikarjuna, Nicholson, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568830/
https://www.ncbi.nlm.nih.gov/pubmed/33069214
http://dx.doi.org/10.1186/s10194-020-01190-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568830/
https://www.ncbi.nlm.nih.gov/pubmed/33069214
http://dx.doi.org/10.1186/s10194-020-01190-7

Ejemplares similares